Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Shelley

Vascular & Interventional Radiology Blackfoot, ID Medical Doctor

NPI 1386685535 CMS profile 488264

98 Poplar St, Blackfoot, ID 83221

Open in the dashboard

General payments

$37,033

95 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Shelley of Blackfoot, ID is reported in the CMS Open Payments database as having received $37,033 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $554 19
2024 General $525 10
2023 General $5,028 19
2022 General $241 7
2021 General $602 12
2020 General $4,761 6
2019 General $25,324 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Shelley
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to David Shelley were reported at $554. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year David Shelley Vascular & Interventional Radiology median Middle half National median
2019 $25,324 $422 $125–$1,555 $163
2020 $4,761 $200 $68–$652 $114
2021 $602 $280 $99–$866 $132
2022 $241 $433 $137–$1,497 $149
2023 $5,028 $506 $152–$2,019 $160
2024 $525 $556 $175–$1,930 $164
2025 $554 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merit Medical Systems Inc $31,891 14 payments
  2. Medtronic, Inc. $2,727 20 payments
  3. Penumbra, Inc. $387 6 payments
  4. Inari Medical, Inc. $361 9 payments
  5. Abbott Laboratories $261 4 payments
  6. Stryker Corporation $244 11 payments
  7. Cook Medical LLC $233 5 payments
  8. Endologix, Inc. $220 4 payments
  9. Medtronic USA, Inc. $211 6 payments
  10. AngioDynamics, Inc. $136 1 payment
  11. Other $361 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $30,350 9 payments
  2. Travel and Lodging $3,470 10 payments
  3. Food and Beverage $3,186 75 payments
  4. Education $27 1 payment
Products named General payments · program years 2019–2025
  1. StabiliT System $16,605 6 payments
  2. ELLIPSYS VASCULAR ACCESS SYSTEM $2,401 13 payments
  3. STAR Tumor Ablation System $555 2 payments
  4. FLOWTRIEVER CATHETER, S $465 12 payments
  5. CT THROMBECTOMY SYSTEM KIT $465 12 payments
  6. ENDOCROSS Device $220 4 payments
  7. Torus Stent Graft System $220 4 payments
  8. KYPHON EXPRESS II KYPHOPAK TRAY $218 4 payments
  9. Indigo $206 4 payments
  10. Supera peripheral stent system $142 2 payments
  11. Other $1,490 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

434

Median for Interventional Radiology: 38

Drug cost

$38,791

Median for Interventional Radiology: $333

Branded share of claims

58.1%

Median for Interventional Radiology: 53%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 47 $36,748
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 59 $784
Clopidogrel Clopidogrel Bisulfate Brand 77 $562
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 69 $309
Cephalexin Generic 55 $196
Ibuprofen Generic 63 $153
Alprazolam Generic 64 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$14,307

Medicare's payments for the services billed

Medicare patients

38

Average age 74

Services billed

111

25 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 68%
Diabetes 39%
Chronic kidney disease 34%
Osteoporosis 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record